ARA-290 / Cibinetide
ARA-290—also known as cibinetide—was developed from erythropoietin biology and is being investigated for a very different purpose than traditional EPO.
Instead of focusing on red-blood-cell production, researchers have studied ARA-290 for its potential to influence inflammatory regulation, injured-cell protection, small-fiber neuropathy, and tissue repair.
Human clinical research available • Still investigationalWhat Is ARA-290?
ARA-290, later called cibinetide, is an investigational 11-amino-acid peptide derived from a specific structural region of erythropoietin.
Erythropoietin is best known for signaling the bone marrow to make red blood cells. Researchers discovered, however, that erythropoietin-related biology also includes pathways involved in cell survival, inflammatory regulation, tissue protection, and repair.
ARA-290 was engineered to investigate those tissue-protective pathways without intentionally producing the erythropoietic effects of conventional EPO.
Erythropoietin vs. ARA-290
Traditional Erythropoietin
EPO activates signaling that stimulates bone marrow production of red blood cells.
Those hematologic effects are useful in appropriate medical conditions but can also create concerns when increased erythropoiesis is not desired.
EPO → Blood production + tissue-protective signalingARA-290 / Cibinetide
ARA-290 was designed to emphasize tissue-protective signaling without producing the same red-blood-cell-stimulating effect.
This allows researchers to investigate EPO-associated repair biology without intentionally increasing erythropoiesis.
ARA-290 → Tissue protection & repair signalingHow Does ARA-290 Work?
The primary proposed target of ARA-290 is commonly called the Innate Repair Receptor, or IRR.
This tissue-protective signaling complex has been described as involving the erythropoietin receptor together with the β-common receptor, CD131.
A Simplified View of the Receptor
Following tissue injury or inflammatory stress, this signaling system has been investigated for roles involving cellular protection, inflammatory regulation, and tissue repair.
Tissue Injury
Nerve or tissue damage creates local inflammatory and cellular stress signals.
Regulate Inflammation
IRR signaling is being studied for its ability to shift inflammatory responses away from prolonged tissue damage.
Protect Injured Cells
Tissue-protective pathways may help support cell survival within an injured or inflamed environment.
Support Repair
The longer-term research question is whether changing that environment can support restoration of nerve and tissue function.
The Key Concept
ARA-290 is not being studied simply as a traditional analgesic. The scientific interest is whether tissue-protective signaling can alter the biological environment surrounding an injured nerve.
Why Is ARA-290 Interesting for Neuropathy?
When peripheral nerves become injured, symptoms can include burning, tingling, electrical sensations, numbness, abnormal sensitivity, temperature changes, or autonomic dysfunction.
Established neuropathic-pain medications can be very useful for reducing symptoms. But symptom control and restoration of damaged nerve tissue are two different goals.
Goal 1: Reduce the Signal
Traditional neuropathic-pain treatment often focuses on reducing:
Burning • Tingling • Pain • Electric sensations • Abnormal sensitivity
Goal 2: Address the Injured Nerve Environment
ARA-290 research asks whether tissue-protective signaling can influence:
Inflammation • Cell survival • Nerve-fiber health • Tissue repair • Functional recovery
An Important Distinction
Evidence of nerve-fiber changes in clinical studies is encouraging, but it is too early to claim that ARA-290 reliably regenerates damaged nerves or reverses neuropathy across different diseases.
Understanding Small-Fiber Neuropathy
Small-fiber neuropathy affects small sensory and autonomic nerve fibers distributed throughout the body.
Sensory Fibers
- Burning discomfort
- Tingling or pins-and-needles sensations
- Shooting or electric sensations
- Temperature sensitivity
- Abnormal sensitivity to touch
- Numbness or altered sensation
Autonomic Fibers
- Sweating regulation
- Heart-rate responses
- Blood-pressure regulation
- Gastrointestinal function
- Temperature regulation
- Other involuntary body processes
Small-Fiber Neuropathy Is Not One Disease
Diabetes, autoimmune disease, sarcoidosis, nutritional deficiencies, toxic exposures, infections, certain medications, metabolic disorders, and other conditions can injure small nerve fibers. Sometimes no clear cause is identified.
What Does the Human Research Show?
ARA-290/cibinetide has progressed beyond animal models into randomized human studies involving patients with small-fiber neuropathy.
Sarcoidosis-Associated Small-Fiber Neuropathy
A blinded, placebo-controlled study evaluated ARA-290 in patients with sarcoidosis-associated small nerve-fiber loss.
Researchers reported improvements in neuropathic symptoms as well as changes in objective measures including corneal small nerve-fiber density.
Objective Nerve-Fiber Measurements
A later randomized study involving 64 patients with sarcoidosis-associated small nerve-fiber loss used corneal confocal microscopy and skin measurements to assess small nerve fibers.
Cibinetide was associated with increased small nerve-fiber abundance in the cornea and skin—an important finding because it goes beyond asking only whether patients reported less pain.
Painful Diabetic Neuropathy
ARA-290 has also been evaluated in adults with type 2 diabetes and painful neuropathy.
Clinical research examined neuropathic symptoms, corneal nerve fibers, metabolic outcomes, and other measures during treatment.
Why the Objective Measurements Matter
Pain scores are important, but they are subjective. Corneal confocal microscopy allows researchers to directly quantify small nerve fibers.
Observing changes in nerve-fiber abundance provides a biological signal that is fundamentally different from simply demonstrating that a patient reports less pain.
ARA-290 & Neuroinflammatory Signaling
Inflammation is a normal part of the response to tissue injury. Immune signaling helps identify damaged tissue and coordinate recovery.
Problems can arise when inflammatory signaling becomes prolonged or continues contributing to nerve dysfunction and sensitization.
A Different Strategy
ARA-290 research is not centered on indiscriminately suppressing inflammation. The proposed strategy is to activate a tissue-protective signaling system that may help shift injured tissue toward survival and repair.
Does ARA-290 Increase Red Blood Cells?
ARA-290 was specifically engineered to investigate erythropoietin-related tissue-protective signaling without intentionally producing the hematologic response associated with conventional EPO.
Designed to Be Non-Erythropoietic
ARA-290 is not intended to function as an erythropoiesis-stimulating therapy. Its research target is the tissue-protective side of erythropoietin biology.
Design Does Not Eliminate the Need for Safety Research
Being engineered to avoid the traditional erythropoietic response does not mean long-term human safety is fully established. Clinical exposure remains much smaller than for widely approved medications.
How Has ARA-290 Been Studied?
Subcutaneous Administration
Subcutaneous administration has been used in published human clinical studies of ARA-290/cibinetide, including neuropathy research.
Because ARA-290 is not an FDA-approved medication, there is no standardized FDA-approved neuropathy dose, treatment cycle, or commercially approved subcutaneous formulation.
Research protocols should not automatically be interpreted as individualized clinical treatment protocols.
What Does the Evidence Actually Show?
Evidence Rating: Human Clinical Research
ARA-290 has progressed beyond purely theoretical or animal research. Randomized human studies provide meaningful evidence supporting continued investigation, particularly in small-fiber neuropathy.
It remains investigational and is not an established FDA-approved neuropathy treatment.
Safety & Important Considerations
ARA-290 has more human safety information than many experimental peptides because it has undergone clinical trials.
The total number of exposed patients, however, remains small compared with established medications used across large populations.
Injection-Site Reactions
Local discomfort or other injection-site reactions are possible with subcutaneous administration.
Hypersensitivity
As with peptide products, hypersensitivity and immunologic reactions remain potential considerations.
Unknown Interactions
Potential interactions with medications, supplements, or other experimental peptides have not been comprehensively characterized.
Long-Term Exposure
Effects of prolonged or repeated use have not been characterized to the degree expected for a widely approved medication.
Product Quality
Purity, sterility, concentration, degradation products, and manufacturing quality matter when injectable products are compounded.
Underlying Diagnosis
Treating symptoms without identifying the cause of neuropathy can delay diagnosis of a metabolic, nutritional, autoimmune, toxic, compressive, or neurologic disorder.
FDA & Regulatory Status
Not FDA Approved
ARA-290/cibinetide is not currently an FDA-approved medication for small-fiber neuropathy, diabetic neuropathy, neuropathic pain, or any other therapeutic indication.
Section 503A Compounding Status
FDA’s May 2026 list places cibinetide (ARA-290) in Category 3: bulk drug substances nominated without adequate support for inclusion on the Section 503A Bulks List.
That compounding classification is separate from FDA drug approval and does not establish clinical safety or effectiveness.
Frequently Asked Questions
Is ARA-290 the same as cibinetide?
Yes. Cibinetide is the name commonly used for ARA-290 in later clinical development.
Is ARA-290 erythropoietin?
No. It was engineered from erythropoietin-related biology but is a separate 11-amino-acid peptide designed to emphasize tissue-protective rather than erythropoietic signaling.
Is ARA-290 a pain medication?
Not in the traditional sense. Its research focus involves inflammatory regulation, cellular protection, and the injured nerve environment rather than simply blocking pain perception.
Has ARA-290 been studied in humans?
Yes. Randomized human clinical studies have investigated ARA-290/cibinetide in small-fiber neuropathy associated with sarcoidosis and type 2 diabetes.
Can ARA-290 regenerate nerves?
Human studies have reported encouraging changes in objective small nerve-fiber measurements. That is promising, but current evidence is not sufficient to claim that ARA-290 reliably regenerates nerves or reverses neuropathy.
Does ARA-290 increase red blood cells?
ARA-290 was specifically designed as a non-erythropoietic peptide so researchers could investigate EPO-associated tissue-protective pathways without intentionally stimulating red-blood-cell production.
Is ARA-290 FDA approved?
No. ARA-290/cibinetide remains investigational.
The Bigger Picture
A nerve does not usually become unhealthy for no reason.
The first question should therefore be:
Why are the nerves being injured?
Interested in Nerve & Neuropathy Support?
Schedule a personalized wellness consultation to discuss your symptoms, metabolic health, health history, potential causes of nerve injury, and available options.
Book a Wellness ConsultationSelected Scientific References
ARA-290 in sarcoidosis-associated small nerve-fiber loss, neuropathic symptoms, and corneal nerve-fiber density.
View on PubMed →
Clinical development of ARA-290 for small-fiber neuropathy.
View on PubMed →
Phase II investigation of ARA-290 in patients with type 2 diabetes and painful neuropathy.
View on PubMed →
Cibinetide and objective small nerve-fiber abundance in the cornea and skin of patients with sarcoidosis-associated neuropathy.
View on PubMed →
Review of innate-repair-receptor activation and ARA-290 research in neuropathy.
View on PubMed →
Current Section 503A bulk-drug-substance nomination status for cibinetide (ARA-290).
View FDA Information →
How it works
A simplified mechanism overview
ARA-290 is designed to interact with tissue-protective signaling pathways rather than the pathways linked to red blood cell production. In simple terms, researchers are interested in whether it may help support how the body responds to inflammation, irritation, and nerve stress.
That does not mean it is a universal solution. Nerve symptoms can involve metabolism, immune signaling, circulation, sleep, stress, and overall recovery. Peptides are only one part of the bigger clinical picture.
